Literature DB >> 514934

Toxic psychosis with antihistamines reversed by physostigmine.

P J Cowen.   

Abstract

A case of toxic psychosis due to antihistamine poisoning is described. The reversal of this state by physostigmine supports the contention that it is caused by an anticholinergic syndrome. The management of antihistamine poisoning is discussed.

Entities:  

Mesh：

Substances：

Year:  1979        PMID： 514934      PMCID： PMC2428090          DOI： 10.1136/pgmj.55.646.556

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN： 0032-5473            Impact factor:   2.401


  6 in total

1.  Physostigmine reversal of antihistamine-induced excitement and depression.

Authors:  J H Lee; H Turndorf; P J Poppers
Journal:  Anesthesiology       Date:  1975-12       Impact factor: 7.892

2.  Reversal of central anticholinergic syndrome in man by physostigmine.

Authors:  R C Duvoisin; R Katz
Journal:  JAMA       Date:  1968-11-25       Impact factor: 56.272

3.  Doxepin overdose. Success with physostigmine and failure with neostigmine in reversing toxicity.

Authors:  P A Janson; J B Watt; J A Hermos
Journal:  JAMA       Date:  1977-06-13       Impact factor: 56.272

4.  Treatment of phenothiazine overdosage with physostigmine.

Authors:  S F Wang; C L Marlowe
Journal:  Pediatrics       Date:  1977-02       Impact factor: 7.124

5.  Anticholinergic poisoning: treatment with physostigmine.

Authors:  B H Rumack
Journal:  Pediatrics       Date:  1973-09       Impact factor: 7.124

6.  Physostigmine. Its use in acute anticholinergic syndrome with antidepressant and antiparkinson drugs.

Authors:  R P Granacher; R J Baldessarini
Journal:  Arch Gen Psychiatry       Date:  1975-03
  6 in total
  1 in total

1.  Beyond the 'purple drank': Study of promethazine abuse according to the European Medicines Agency adverse drug reaction reports.

Authors:  Stefania Chiappini; Fabrizio Schifano; John Martin Corkery; Amira Guirguis
Journal:  J Psychopharmacol       Date:  2021-01-10       Impact factor: 4.153
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.